Intrastromal Injection of Bevacizumab in the Management of Corneal Neovascularization: About 25 Eyes
Open Access
- 17 August 2016
- journal article
- research article
- Published by Hindawi Limited in Journal of Ophthalmology
- Vol. 2016, 1-4
- https://doi.org/10.1155/2016/6084270
Abstract
Introduction. Corneal neovessels are a major risk factor for corneal graft rejection, due to the loss of the immune privilege. The purpose of this study is to evaluate the effectiveness of intrastromal injection of bevacizumab in the treatment of corneal neovascularization.Material and Methods. This is a prospective study that included 25 eyes of 22 patients with deep corneal neovessels, treated with intrastromal injections of bevacizumab.Results. The average age of patients was 31 years ranging from 16 to 44 years. The causes of neovascularization were dominated by herpetic keratitis (10 cases). The evolution was marked by complete regress of neovessels in 16 patients, partial regress in 6 cases, and reduced opacity and improved visual acuity in 5 patients. No side effects were noted.Discussion. Short-term results demonstrated the effectiveness of intrastromal injection of bevacizumab in the treatment of corneal neovessels. It may be an option or a complement to other useful treatments in stabilizing or improving vision.Conclusion. Bevacizumab is an effective additional treatment for the improvement of corneal transplants prognosis with preoperative corneal neovascularization.Keywords
This publication has 22 references indexed in Scilit:
- Ranibizumab Injection for Corneal Neovascularization Refractory to Bevacizumab TreatmentKorean Journal of Ophthalmology, 2014
- Néovascularisation cornéenne : aspects épidémiologiques, physiopathologiques et cliniquesJournal Français d'Ophtalmologie, 2013
- Deep Intrastromal Injection of Bevacizumab for the Management of Corneal NeovascularizationCornea, 2013
- Intrastromal injection of bevacizumab in patients with corneal neovascularization.Arquivos Brasileiros de Oftalmologia, 2012
- Combined Use of Subconjunctival and Intracorneal Bevacizumab Injection for Corneal NeovascularizationCornea, 2011
- Treatments for Corneal Neovascularization: A ReviewCornea, 2011
- Bevacizumab (Avastin) eye drops inhibit corneal neovascularizationAlbrecht von Graefes Archiv für Ophthalmologie, 2007
- Corneal neovascularizationCurrent Opinion in Opthalmology, 2001
- Fine needle diathermy occlusion of corneal vessels.2000
- Hydrocortisone inhibits platelet prostaglandin and endothelial prostacyclin productionPharmacological Research Communications, 1981